AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

iTeos Therapeutics to Present at UBS Global Healthcare Conference

May 13, 2019

iTeos Therapeutics to Present at UBS Global Healthcare Conference

Gosselies, Belgium and Cambridge, MA – May 13, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos, will present at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 11:30 a.m. ET in New York, NY.

About iTeos Therapeutics

iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in the second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.

For further information, please contact:Michel Detheux, CEOiTeos Therapeutics info@iteostherapeutics.com

Amber Fennell, Mathew Neal, Sukaina Virji and Catherine LondonConsilium Strategic Communications+44 203 709 5700 iteos@consilium-comms.com

Sarah McCabeStern Investor Relations, Inc.+ 1 212 362 1200 iTeos@sternir.com

All contents © copyright 2019 The Associated Press.All rights reserved.